QHP Closes $1.1 Billion Azurity Continuation Vehicle

Deal Overview QHP Capital announced the closing of a $1.1 billion single-asset continuation vehicle for Azurity Pharmaceuticals. The transaction offers existing limited partners a choice between taking liquidity and rolling into a new vehicle designed to support the company’s next phase of expansion. HarbourVest led the transaction, with Pantheon participating as a significant investor and Audax Strategic Capital contributing through both the continuation vehicle and a separate structured growth investment. Why the Deal Stands Out It is a large-scale single-asset GP-led transaction centered on a healthcare asset with visible strategic growth plans. The structure combines investor liquidity with new capital for organic growth, licensing, and potential acquisitions. Blue-chip secondaries investors are backing the sponsor’s conviction rather than forcing an early exit. QHP said the deal is intended to support Azurity’s long-term value creation plan while offering liquidity to existing LPs. Read-Through for GP-Led Markets This transaction reinforces the continued maturation of continuation vehicles from niche solutions into mainstream capital-formation tools. Rather than selling a prized asset outright, sponsors can now recapitalize ownership, reset hold periods, and bring in specialist buyers that underwrite concentrated exposure. For LPs, that means more flexible exit options. For GPs, it means the ability to preserve upside in assets that still have meaningful runway, especially when public listings or strategic exits remain uncertain. Why This Matters for Private Markets The Azurity deal shows that high-quality GP-leds remain one of the most scalable answers to the private-markets liquidity gap. When distributions are slow, continuation vehicles can create liquidity without sacrificing ownership of standout assets. It also demonstrates that single-asset GP-led deals are increasingly functioning as a capital-markets bridge for mature private companies. In today’s environment, the best secondaries transactions are not just exits; they are structured growth financings with alignment built in.